Shineco (NASDAQ:SISI – Get Free Report) and ProPhase Labs (NASDAQ:PRPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.
Valuation and Earnings
This table compares Shineco and ProPhase Labs”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
| ProPhase Labs | $5.05 million | 0.09 | -$53.36 million | ($3.13) | -0.02 |
Analyst Recommendations
This is a summary of current recommendations for Shineco and ProPhase Labs, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
Risk and Volatility
Shineco has a beta of -1.89, indicating that its share price is 289% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.
Insider & Institutional Ownership
4.1% of Shineco shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Shineco and ProPhase Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
Summary
Shineco beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
